A hafft1 cell

Abstract

The invention belongs to the field of biotechnology, and in particular relates to a HAFFT1 cell and a preparation method thereof. The cells are modified with TCR-T technology, and the modified T cells are then knocked out of immunosuppressive targets, which precisely protects the specific killer T cells from inhibition in vivo and improves the lethality of T cells against tumor cells . The proportion of specific T cells (TCR+) that recognize tumor antigens in the cells transformed by the HAFFT1 program is over 80%.

Description

Technical field: [0001] The invention belongs to the field of biotechnology, and in particular relates to a HAFFT1 cell and a preparation method thereof. Background technique: [0002] At present, in terms of tumor-specific immunotherapy, the existing LAK, DC, CIK, and DC-CIK cells and methods have basically been proved to be ineffective, while NK, CAR-NK, TIL and other cell technologies have yet to mature. CAR- T cells also have shortcomings in safety and solid tumor therapy. [0003] In the prior art, DCs are generally modified to present T cells to produce specific killing. Some laboratories are trying to use viruses as vectors to transfect and present T cells to induce specific killing of T cells. We have also used mutant hybrid peptides to directly stimulate PBMCs to induce T cells. There are also laboratories using TCR-T technology to target the presentation of MAGE A3 antigen. [0004] The above treatment methods are immature, especially the in vitro induction of ...

AI Technical Summary

Problems solved by technology

[0005] None of the above schemes consider the self-protection technology of T cells, so that a small number of specific T cells directly face the powerful tumor microenvironment

Images